covidien plc (COV:New York Consolidated)
Transactions by COVIDIEN PLC (COV) in the last 6 months
The Spectranetics Corporation (Nasdaq:SPNC) agreed to acquire Stellarex DCB platform from Covidien plc (NYSE:COV) for $30 million in cash on October 31, 2014. In connection with the transaction, Spectranetics and Covidien are entering into a product supply agreement pursuant to which Covidien agrees to supply certain angioplasty balloon catheter products to Spectranetics, subject to the terms and conditions set forth in the agreement. The agreement will have an initial ...
Covidien plc (NYSE: COV) acquired Sapheon, Inc. from Main Line Equity Partners, LLC and others on August 28, 2014. The transaction will be slightly dilutive to adjusted earnings, and is not expected to be material to results. Diane Holt Frankle of Kaye Scholer LLP and Simon Inman, Adam Rosenblum and Theresa Gatesacted of Carle, Mackie, Power & Ross LLP acted as legal advisor to Sapheon, Inc. Sally A. Thurston of Skadden, Arps, Slate, Meagher & Flom, L.L.P. acted as legal ...
Kaye Scholer LLP
Covidien plc (NYSE:COV) acquired Reverse Medical Corporation from a group of sellers on August 22, 2014. The sellers included BioStar Ventures, Early Stage Partners, LP, Emergent Medical Partners, NBGI Ventures, Terra Rossa Capital Pty Ltd, yet2Ventures and others. Covidien will report the Reverse Medical business as part of its Neurovascular product line in the Medical Devices segment.
Early Stage Partners, LP
Emergent Medical Partners
Terra Rossa Capital Pty Ltd
|No competitor information is available for COV.|
|View Industry Companies|
|No financial data is available for COV.|